FDA approves Neurocrine's Ingrezza for tardive dyskinesia

Neurocrine Biosciences Inc. (NASDAQ:NBIX) jumped $7.76 (19%) to $49.24 in early after-hours trading after it said FDA approved Ingrezza valbenazine to treat tardive dyskinesia. Ingrezza is the only drug FDA has approved for the indication.

Neurocrine said Ingrezza will be "in the distribution channel next week and will be available through a select pharmacy network." A full commercial launch is due to begin May 1...